Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- B ALL
- Diffuse Large B Cell Lymphoma
- DLBCL
- DLBCL Activated B-Cell Type
- DLBCL Germinal Center B-Cell Type
- DLBCL Unclassifiable
- Dlbcl-Ci
- DLBCL, Nos Genetic Subtypes
- HGBL
- HGBL, Nos
- Type
- Interventional
- Phase
- Early Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04512716
- Collaborators
- Actinium Pharmaceuticals
- Investigators
- Principal Investigator: Mark B Geyer, MD Memorial Sloan Kettering Cancer Center
Get Well Soon